Evidence map›Paper›PMID 39693071›Full record

ArticleJAMA network open2024

GOLD COPD Exacerbation History Categories and Disease Outcomes.

Kiki Waeijen-Smit, Daphne E M Peerlings, Rudolf A Jörres, Henrik Watz, Robert Bals, Klaus F Rabe, Claus F Vogelmeier, Tim Speicher, Martijn A Spruit, Sami O Simons and 3 more

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Five-Year Survival and Associated Factors in COPD Patients in Colombia: A Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kiki Waeijen-SmitDepartment of Research and Development, Ciro, Horn, the Netherlands.
Daphne E M PeerlingsDepartment of Research and Development, Ciro, Horn, the Netherlands.
Rudolf A JörresInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Munich, Germany.
Henrik WatzLungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Robert BalsDepartment of Internal Medicine V-Pulmonology, Allergology, Critical Care Medicine, Saarland University Hospital, Homburg, Germany.
Klaus F RabeDepartment of Medicine, Christian Albrechts University Kiel, Kiel and LungenClinic Grosshansdorf (Members of the German Center for Lung Research), Grosshansdorf, Germany.
Claus F VogelmeierDepartment of Medicine, Pulmonary, Critical Care and Sleep Medicine, Philipps-University of Marburg, Member of the German Center for Lung Research, Marburg, Germany.
Tim SpeicherDepartment of Medicine, Pulmonary, Critical Care and Sleep Medicine, Philipps-University of Marburg, Member of the German Center for Lung Research, Marburg, Germany.
Martijn A SpruitDepartment of Research and Development, Ciro, Horn, the Netherlands.
Sami O SimonsDepartment of Respiratory Medicine, Research Institute of Nutrition and Translational Research in Metabolism, Faculty of Health Medicine and Life Sciences, Maastricht University Medical Centre+, Maastricht, the Netherlands.
Sarah Houben-WilkeDepartment of Research and Development, Ciro, Horn, the Netherlands.
Frits M E FranssenDepartment of Research and Development, Ciro, Horn, the Netherlands.
Peter AlterDepartment of Medicine, Pulmonary, Critical Care and Sleep Medicine, Philipps-University of Marburg, Member of the German Center for Lung Research, Marburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Previous exacerbations of chronic obstructive pulmonary disease (ECOPD) are associated with future events. For more than a decade, patients at high risk have been defined as individuals with a history of 2 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months, and treatments have been allocated accordingly, but these cutoffs lack validation. Objectives: To validate ECOPD history categories by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and explore alternative cutoffs to estimate moderate and severe ECOPD and all-cause mortality in COPD. Design, Setting, and Participants: This cohort study analyzed data from patients with COPD in the German COPD and Systemic Consequences-Comorbidities Network (COSYCONET) study. Patients were recruited from September 2010 to December 2013. Analyses were conducted in September 2023 to August 2024. Main Outcomes and Measures: Risk of moderate and severe (ie, with hospitalization) ECOPD and all-cause mortality over a 4.5-year follow-up period were assessed using binomial logistic regressions and area under the receiver operating characteristic curves (AUROCs) with 95% CIs. Results: Among 2291 patients with COPD GOLD categories 1 to 4 (mean [SD] age, 65 [8] years; 1396 male [60.9%]), the mean (SD) estimated forced expiratory volume in the first second of expiration was 52.5% (18.6%). ECOPD history categories by GOLD had an AUROC of 0.63 (95% CI, 0.60-0.65) and 0.62 (95% CI, 0.58-0.66) to estimate moderate and severe ECOPD, respectively. A single previous moderate ECOPD within 12 months more accurately estimated future moderate and severe ECOPD (AUROC, 0.66; 95% CI, 0.64-0.69), and in line with GOLD, 1 previous severe ECOPD within 12 months estimated moderate and severe ECOPD (AUROC, 0.63; 95% CI, 0.60-0.67). The 4-year mortality rate was 219 patients (9.6%). Patients with 3 or more previous moderate ECOPD (odds ratio, 2.18; 95% CI, 1.27-3.72) or 1 or more previous severe ECOPD (odds ratio, 1.57; 95% CI, 1.29-1.91) within 12 months were more likely to die compared with patients without prior ECOPD. Conclusions and Relevance: This study's findings suggest a limited estimative performance of ECOPD history categories by GOLD. Novel cutoffs were suggested, categorizing patients as without exacerbations or with high-risk exacerbations based on a history of 1 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months.

Indexed as

Disease ProgressionPulmonary Disease, Chronic ObstructiveSeverity of Illness IndexAgedCohort StudiesFemaleForced Expiratory VolumeGermanyHumansMaleMiddle Aged

Identifiers

PMID39693071
PMCPMC11656261

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.